Search for a trial

Primary Cerebral Lymphoma at UMCU and St Antonius

Conducting research into the role of CSF and blood parameters of patients with CNS lymphoma, focused on improving the diagnostics, identification of biomarkers ('liquid biopsy'), and evaluation of therapy effect.

A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation

This study has been transitioned to CTIS with ID 2023-506270-13-00 check the CTIS register for the current data. The primary objective is to determine superiority of MB CART2019.1 treatment compared to standard-of-care (SoC) therapy with R GemOx (…

The Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2023-504805-35-00 check the CTIS register for the current data. Dose Escalation PhasePrimary - Evaluate the safety and tolerability of epcoritamab in combination with other agents Secondary-…

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

This study has been transitioned to CTIS with ID 2023-507695-52-00 check the CTIS register for the current data. To compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor…

A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2024-511979-15-00 check the CTIS register for the current data. Primary objective: • To compare progression free survival (PFS, of patients randomized to investigational point-of-care (PoC) ARI-0001…

A phase 2 immunoPET imaging study with ZED88082A/CED88004S in patients with Large B-cell lymphoma before and after CD19-directed CAR T-cell therapy

Primary objectives:The objective is to study the distribution of CD8+ T-cells before and after CAR T-cell therapy in the patient by ZED88082A/CED88004S-PET imaging. We will correlate the pretreatment CD8+ T-cell distribution and CD8+ CAR T-cell…

A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma

This study has been transitioned to CTIS with ID 2022-502661-23-00 check the CTIS register for the current data. The primary objective of the study is to evaluate the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects…

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

This study has been transitioned to CTIS with ID 2024-511616-24-00 check the CTIS register for the current data. Primary ObjectivesPhase 1a:• Evaluate the safety of KITE-363 in subjects with r/r B-cell lymphoma• Determine the dose level(s) for Phase…

Phase 1b/2, Open Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2023-505347-38-00 check the CTIS register for the current data. The primary objectives of the study are to characterize the safety and toxicity profiles of epcoritamab when co-administered with anti-…

Testing of a new antibody therapy using blood from children with B-cell Non-Hodgkin lymphoma.

Within the immunotherapy group, a new panel of anti-CD20 monoclonals have been generated that are currently produced as chimeric IgG and IgA formats. We intend to demonstrate the efficacy and the anticipated superiority of IgA versus IgG and…

An Open-label, Phase 2 Study of ACP-196 in Subjects
with Waldenström Macroglobulinemia

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and activity of ACP-196 in treating subjects with Waldenström disease.

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

This study has been transitioned to CTIS with ID 2023-503916-33-00 check the CTIS register for the current data. Primary Objective• Evaluate the efficacy of loncastuximab tesirine combined with rituximab compared to standard immunochemotherapy…

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton*s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

This study has been transitioned to CTIS with ID 2023-510541-25-00 check the CTIS register for the current data. This study*s phase 1a primary objectives are:• To evaluate the safety and tolerability of BTK degrader NX-5948, when taken orally, in…

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator*s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

This study has been transitioned to CTIS with ID 2023-504830-23-00 check the CTIS register for the current data. Compare the clinical efficacy of Epcoritamab to SOC (R-GemOx or BR)

A Phase 3, Randomized, Open-Label, Multicenter Study
Comparing the Efficacy and Safety of the Bruton*s Tyrosine
Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects
with Waldenström*s Macroglobulinemia (WM)

Primary (Cohort 1)* To compare the efficacy of zanubrutinib (BGB-3111) vs ibrutinib in subjects with MYD88MUT WMSecondary (Cohort 1) * To further compare the efficacy, clinical benefit, and anti-lymphoma effects of BGB-3111 vs ibrutinib in subjects…

An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma

The purpose of this study is to evaluate the efficacy, activity, safety, pharmacodynamics and pharmacokinetics of ACP-196 in treating subjects with Mantle Cell Lymphoma (MCL)

Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

Primary objective:- To confirm in a multicenter setting an improvement in EFS to 95% at 2 years of DA-EPOCH-R in patients with newly diagnosed high risk Burkitt lymphoma as compared to an expected EFS of 72% at 2 years for the control arm R-CODOX-M/…

MUSCLE study - Mitochondrial dysfUnction: a key player in doxorubicin-induced Skeletal and Cardiac muscLE damage?

To demonstrate the ability of using non-invasive 31P-MRS to monitor changes of in vivo markers of mitochondrial function in skeletal and cardiac muscles (i.e., skeletal muscle PCr recovery rate constant and cardiac PCr/ATP ratio) in DLBCL patients…

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

This study has been transitioned to CTIS with ID 2023-509908-15-00 check the CTIS register for the current data. All primary and secondary objectives will compare zanubrutinib (also known as BGB-3111) plus rituximab followed by zanubrutinib…

Response assessment of post-transplant lymphoproliferative disorder with 18F-FDG-PET/CT and minimal residual disease monitoring, a multicenter multinational feasibility study

1 - To determine the feasibility of MRD detection using next generation sequencing (NGS) on circulating tumor DNA (ctDNA) from PTLD patients using a gene panel previously used in diffuse large B-cell lymphoma (DLBCL) 2 - To explore the mutational…